Singapore, April 9 -- Japan headquartered pharma company Eisai Co. has announced that its French sales subsidiary Eisai S.A.S. has entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the Territory" for the antipsychotic, Loxapac (generic name: loxapine) and the Parkinson's disease treatment Parkinane LP (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics, based in UK.

Following the signature of this agreement, a transition period had opened during which the required implementation steps will be carried out in order for CNX to become able to operate directly the business, including the regulatory steps for the transfer of the relevant marketing authorisations and exploitan...